| Gefitinib |
BC087858 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
BE244504 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
BG188549 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
ENSG00000118412.8 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000149656.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000157152.12 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000163597.10 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000170590.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000170590.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000171889.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000172965.10 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000172965.10 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000174403.11 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000175147.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000177112.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000177133.6 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000177406.4 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000177993.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000178248.10 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000178977.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000178977.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000179219.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000180279.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000180458.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000180769.4 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000181097.5 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000182021.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000185168.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000185186.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000185203.7 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000185904.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000186019.10 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000186594.8 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000186615.6 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000186615.6 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000188660.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000189238.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000189419.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000189419.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000196364.7 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000196668.3 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000196960.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000197099.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000197332.7 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000197558.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000198221.7 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000203280.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000203288.3 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000203441.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000203499.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000203588.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000203709.5 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000203987.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000204054.7 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000204241.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000204588.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000204625.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000204815.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000204815.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000204832.5 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000204832.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000204929.7 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000205488.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000205611.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000205628.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000205890.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000205959.3 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000206195.6 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000206417.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000212163.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000212978.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000213468.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000213468.3 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000213863.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000213971.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000214049.6 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000214049.6 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000214049.6 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000214401.4 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000214432.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000214559.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000214650.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000214733.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000214770.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000214773.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000214894.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000214894.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000214922.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000214955.5 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000214955.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000215023.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000215068.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000215159.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000215190.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000215241.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000215447.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000215458.4 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000215533.4 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000215769.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000215841.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000215841.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000217576.7 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000219665.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000222041.6 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000222041.6 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000223461.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000223462.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000223477.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223477.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000223478.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000223485.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000223561.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223571.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000223598.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000223598.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000223598.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000223635.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000223704.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000223725.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000223734.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000223734.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223764.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223768.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000223770.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223783.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223784.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223784.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000223813.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000223813.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000223813.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000223821.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000223821.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000223884.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223935.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000223956.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000223960.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000223975.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224057.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000224063.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000224079.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000224142.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224189.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000224189.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000224216.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000224251.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000224349.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224363.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224468.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000224478.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000224597.5 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000224606.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000224621.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224652.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224655.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224713.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224733.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224738.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000224745.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000224745.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000224794.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224794.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000224818.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000224818.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224822.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224888.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000224897.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000224899.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000224934.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000224959.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000224969.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000224984.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000224985.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000224992.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000225037.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000225037.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000225077.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000225077.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000225084.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000225087.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000225111.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225111.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000225127.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225138.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225140.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225152.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225163.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000225163.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000225177.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000225205.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225210.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000225213.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000225218.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000225235.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225235.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000225285.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000225377.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000225408.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000225439.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225439.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000225439.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000225442.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000225470.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000225527.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000225532.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000225541.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000225578.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000225620.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225643.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000225656.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000225721.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000225725.4 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000225744.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000225767.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000225778.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225798.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000225891.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225929.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225930.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225945.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000225948.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000225953.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225969.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000225982.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000225982.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000226051.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000226125.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000226125.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000226276.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000226287.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000226287.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000226328.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000226332.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000226334.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000226352.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000226363.3 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000226377.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000226377.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000226386.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000226386.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000226445.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000226453.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000226562.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000226562.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000226711.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000226756.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000226780.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000226828.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000226833.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000226833.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000226851.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000226852.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000226883.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000226890.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000226891.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000226913.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000226920.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000226953.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227014.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000227039.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227053.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000227071.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000227117.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000227161.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000227172.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000227210.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000227214.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000227245.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000227248.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227285.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227375.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000227403.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227403.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227409.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000227431.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000227432.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227438.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227477.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227479.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227486.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227512.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000227518.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000227518.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000227598.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000227603.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227617.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000227630.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000227630.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000227640.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000227674.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000227674.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000227698.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000227702.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227704.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000227726.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227811.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227885.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227888.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000227895.4 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000227953.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000227953.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000227953.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000227954.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000227959.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228010.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000228043.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000228060.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228067.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228107.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228113.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000228126.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000228135.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228137.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000228150.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000228203.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228204.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000228221.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000228274.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000228313.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228363.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000228408.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228452.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000228470.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000228481.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228485.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000228486.5 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000228526.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000228526.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228527.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228536.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000228540.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000228544.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000228544.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000228577.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228604.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000228614.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000228629.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228643.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228643.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228649.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000228686.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000228692.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228701.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000228723.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000228737.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000228737.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228741.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000228763.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000228791.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228793.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000228794.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228802.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000228838.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000228878.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000228886.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228906.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000228917.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000228918.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000228988.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000229021.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229109.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000229167.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229180.4 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000229180.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000229190.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000229190.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000229267.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000229278.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000229373.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000229388.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000229400.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229401.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000229444.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000229491.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229525.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000229536.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229539.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000229582.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229645.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229647.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000229656.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229672.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229688.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000229688.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000229766.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000229780.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000229801.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000229841.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000229848.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000229852.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000229852.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000229852.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000229905.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000229905.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000229915.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000229952.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000229955.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000229956.5 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000229980.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000229989.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000229989.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000229990.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000230013.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000230020.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230021.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000230054.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000230061.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230068.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000230074.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230082.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230082.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000230082.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000230090.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230107.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000230124.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000230131.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000230133.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230176.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000230177.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000230212.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000230239.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230289.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000230303.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000230408.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230423.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000230423.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230438.5 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000230439.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230461.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230487.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000230487.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000230499.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000230499.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230513.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000230550.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000230552.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230561.3 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000230658.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000230698.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230699.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230724.5 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000230751.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000230753.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000230798.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000230812.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000230836.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000230836.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000230844.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000230850.3 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000230925.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000230939.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000231113.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000231128.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231134.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000231172.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000231187.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000231201.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000231212.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000231242.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000231298.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000231310.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000231367.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231407.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000231439.3 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000231481.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231483.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231512.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000231527.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231530.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231551.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000231563.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000231607.4 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000231612.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000231616.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000231654.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000231709.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000231709.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231728.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000231728.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231734.4 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000231742.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000231764.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000231789.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000231840.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000231865.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000231865.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000231871.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000231889.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000231890.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000231920.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000231948.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000231948.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000231966.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000231999.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232081.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232093.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000232151.5 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000232151.5 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000232151.5 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000232164.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232224.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232259.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232259.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000232290.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232298.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000232316.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232386.5 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232401.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232487.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000232504.4 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000232519.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000232527.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000232533.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000232586.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232600.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000232611.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232623.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000232633.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000232633.3 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000232648.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000232677.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232694.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000232712.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000232725.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232729.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000232739.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000232759.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000232784.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232807.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000232814.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000232874.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000232909.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000232940.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000232973.7 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000232973.7 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000232977.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233006.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233008.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000233013.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233033.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233061.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000233221.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233237.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233255.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233429.5 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000233483.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233509.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000233554.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000233554.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000233590.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233593.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000233602.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000233694.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233694.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233757.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233757.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000233760.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000233785.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233799.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000233834.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233844.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233845.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000233845.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000233845.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233848.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000233854.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000233864.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233885.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233901.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233901.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000233901.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000233926.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000233930.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000233967.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000233993.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000234019.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000234084.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000234111.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000234111.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234147.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234155.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234156.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234174.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234183.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000234185.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000234199.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000234215.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000234215.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234292.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234336.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234428.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234449.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000234449.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000234456.3 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000234459.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000234546.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000234546.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234546.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000234571.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000234650.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000234665.4 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000234678.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000234678.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000234678.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234690.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000234694.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234695.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000234703.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234705.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000234753.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000234772.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000234899.5 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000234899.5 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000234913.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000234996.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000234997.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000234998.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000235033.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235066.4 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000235072.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235091.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000235092.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000235119.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000235119.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000235121.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000235121.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235151.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000235185.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235214.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000235244.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235262.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000235295.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235298.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000235319.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000235319.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000235522.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235523.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235526.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000235527.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000235529.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000235560.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000235586.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000235609.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000235652.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235664.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000235703.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000235724.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235724.4 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000235760.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235772.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000235781.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235823.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000235831.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000235852.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000235903.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000235954.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000235979.4 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000236016.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000236017.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000236051.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000236051.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000236116.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236153.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236188.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000236204.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000236206.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000236212.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000236301.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236305.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236305.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236333.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236337.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000236383.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000236384.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236390.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236393.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000236427.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236438.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000236438.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236451.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236467.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236519.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000236537.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236540.3 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000236545.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000236581.4 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000236601.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000236601.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000236618.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236641.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000236703.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000236703.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000236711.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236743.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000236743.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236753.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236772.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000236772.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000236778.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236799.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236810.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000236824.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000236830.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000236830.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000236871.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000236889.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000236933.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000236983.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000236986.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000236986.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000236991.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000237057.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000237073.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237094.7 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000237126.4 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000237166.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237187.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237328.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000237336.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237373.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000237416.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000237416.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237424.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237424.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000237453.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237481.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000237502.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000237513.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000237520.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000237594.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000237609.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000237685.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000237687.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000237753.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000237773.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000237883.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000237883.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000237940.3 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000237943.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000237945.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000237975.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000237976.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000237976.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000237978.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000237998.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000238005.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000238018.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000238035.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000238113.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000238120.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000238140.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000238198.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000238260.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000238260.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000238279.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000238280.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000239335.4 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000239377.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000239377.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000239552.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000239608.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000239664.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000239705.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000239774.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000239774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000239906.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000240005.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000240291.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000240291.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000240350.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000240453.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000240553.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000240618.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000240754.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000240758.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000240875.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000240922.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000240996.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000241180.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000241211.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000241472.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000241544.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000241570.4 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000241599.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000241772.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000241860.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000242048.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000242125.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000242136.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000242147.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000242242.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000242474.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000242516.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000242540.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000242553.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000242569.3 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000242686.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000242759.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000242798.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000243055.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000243193.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000243230.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000243243.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000243389.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000243433.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000243479.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000243485.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000243629.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000243701.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000243766.3 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000243885.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000243885.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000243902.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000244040.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000244040.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000244265.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000244265.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000244306.5 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000244327.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000244541.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000244541.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000244791.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000244879.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000244998.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000245059.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000245311.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000245479.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000245479.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000245573.3 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000245573.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000245648.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000245711.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000245729.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000245750.3 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000245857.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000245937.3 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000246090.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000246130.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000246225.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000246228.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246339.4 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000246375.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246422.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000246465.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000246526.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000246526.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246528.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246560.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000246640.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000246731.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000246740.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000246740.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000246740.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246763.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246790.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000246859.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000246859.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000246859.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246863.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000246898.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000246898.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000246898.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000246982.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000247095.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000247134.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000247137.4 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000247287.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000247287.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000247372.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000247381.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000247516.3 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000247679.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000247708.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248027.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248027.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000248079.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000248092.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248100.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248100.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000248103.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248103.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000248125.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248228.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248238.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000248240.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248268.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248323.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000248371.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248429.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248445.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248473.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000248479.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248494.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000248514.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248515.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000248554.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248596.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248599.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000248682.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248714.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248724.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000248734.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000248758.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248773.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000248773.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000248774.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000248774.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248846.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248866.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000248884.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248890.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248896.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248925.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000248949.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248964.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000248968.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000248996.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249035.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249042.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249042.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000249084.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249131.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000249145.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249167.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249173.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249216.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000249252.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249293.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000249310.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000249430.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000249476.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249476.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249476.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000249492.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249550.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249572.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249584.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249593.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000249593.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000249609.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000249610.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000249610.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249641.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249650.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249669.3 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249684.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249700.4 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000249738.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249781.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000249786.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249790.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000249803.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000249825.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000249825.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249859.3 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000249870.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000250012.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000250027.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000250072.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250073.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000250075.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000250101.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250131.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250132.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000250220.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000250240.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000250267.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000250295.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000250509.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250522.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000250590.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250604.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250608.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000250697.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000250740.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250742.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000250765.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000250846.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000250874.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000250900.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000250909.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000250948.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000250994.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000250999.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000250999.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000251003.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000251128.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251129.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000251230.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000251281.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251292.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251298.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000251298.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000251301.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251324.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000251330.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000251330.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000251359.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000251379.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251381.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000251432.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000251455.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000251556.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000251556.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000251556.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000251603.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251603.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000251611.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000251611.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251613.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000251615.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000251661.3 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000251675.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000251675.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000251687.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000253121.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253182.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253197.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000253230.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000253284.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000253315.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000253406.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253476.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253477.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000253490.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253552.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000253553.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253559.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000253618.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000253636.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253641.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000253649.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000253671.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000253696.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000253706.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000253708.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000253708.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000253712.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000253715.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253799.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000253824.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253837.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000253878.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000253880.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000253893.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000253911.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253925.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253930.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000253948.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000253972.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000253972.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000253983.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254039.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000254109.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000254109.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000254109.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254109.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000254162.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000254165.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000254208.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000254251.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254267.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000254267.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254286.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000254288.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254338.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000254343.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000254362.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000254389.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000254414.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000254432.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000254438.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000254459.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000254468.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000254486.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254533.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254538.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000254539.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000254551.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000254577.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000254604.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000254631.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000254639.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000254676.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000254676.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000254699.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000254734.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254791.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000254812.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000254842.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254842.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000254862.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000254900.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000254907.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000254911.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000254951.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254973.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000254973.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000254981.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255008.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000255045.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000255045.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255145.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000255153.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000255165.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000255201.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255229.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000255247.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000255247.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000255248.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255299.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000255325.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255367.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000255372.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255382.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255421.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000255474.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000255474.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255474.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000255495.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000255521.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000255557.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000255669.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000255670.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000255717.2 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000255843.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000255867.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000255867.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000255893.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000255983.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000255989.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000256050.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000256084.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000256124.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000256128.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000256146.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000256196.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000256237.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000256278.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000256381.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000256433.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000256433.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000256481.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000256603.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000256670.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000256712.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000256789.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000256789.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000256940.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000256973.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000257027.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000257038.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000257084.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000257086.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000257135.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000257151.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000257176.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000257191.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000257252.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000257256.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000257279.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000257279.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000257279.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000257346.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000257366.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000257438.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000257474.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000257475.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000257497.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000257507.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000257527.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000257557.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000257613.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000257621.3 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000257636.2 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000257647.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000257671.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000257671.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000257698.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000257702.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000257732.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000257890.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000257894.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000257910.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000257964.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258086.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000258086.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000258172.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000258175.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258199.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000258301.2 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000258308.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258323.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000258334.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000258337.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258343.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000258344.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000258355.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258414.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000258441.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258442.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000258443.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000258479.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258521.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000258535.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000258537.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258553.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000258593.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258658.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000258673.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000258682.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000258682.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000258711.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000258725.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000258777.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258798.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000258809.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000258825.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000258851.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258851.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000258882.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000258882.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258903.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000258903.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258929.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000258959.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000258983.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000259031.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259038.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259038.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259048.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000259054.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259062.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259065.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000259070.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000259081.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259083.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259087.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259088.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000259135.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259153.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259158.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000259182.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259201.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000259209.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259212.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000259212.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000259242.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259287.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259319.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000259327.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259336.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000259342.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259343.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000259354.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259396.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259396.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000259408.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259416.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000259418.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000259424.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259424.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259426.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000259437.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259438.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000259445.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259448.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259462.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000259473.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259488.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259514.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259520.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000259520.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000259540.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000259548.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000259553.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000259579.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259583.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259606.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000259617.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259618.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259644.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259656.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259673.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000259678.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259692.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259694.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000259705.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000259735.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000259744.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259758.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259762.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000259768.3 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259771.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259772.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259782.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259783.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259783.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000259793.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259796.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259796.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259826.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000259840.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259843.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000259894.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259901.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000259901.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000259925.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000259953.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000259959.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000259969.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260011.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260021.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260035.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260038.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260051.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260077.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260095.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000260123.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260132.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260132.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000260163.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260177.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000260179.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000260193.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000260231.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000260248.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000260252.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260265.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260269.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260278.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000260316.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260328.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260351.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260352.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260361.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000260369.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260388.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000260394.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260396.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260400.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000260404.2 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260430.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260447.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000260475.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260475.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260475.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260517.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000260528.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260534.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260536.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260545.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260572.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260572.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000260579.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260583.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000260585.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000260589.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260592.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260593.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260597.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000260613.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260616.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000260618.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000260633.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260635.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000260635.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260641.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000260641.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000260645.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260646.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000260648.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260655.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260672.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260719.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260742.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260742.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260742.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000260743.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260743.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000260744.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260774.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260787.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260792.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000260796.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000260798.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260830.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260831.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260833.2 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260837.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260855.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000260855.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000260891.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000260910.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000260911.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000260917.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000260920.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260920.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000260922.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260923.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260931.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260936.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260938.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000260948.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000260954.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000260986.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260988.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000260989.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000260992.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261000.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261003.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261005.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261019.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261037.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261040.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000261043.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000261049.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261068.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261068.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261068.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261069.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261101.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000261104.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261114.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261118.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000261140.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000261168.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261168.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000261172.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261183.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261183.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261183.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261187.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000261195.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000261200.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261211.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261211.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261220.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261253.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000261254.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261267.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261268.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261270.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261280.2 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000261288.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000261298.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000261338.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000261338.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000261357.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261373.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261392.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261396.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261404.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261404.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000261420.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000261425.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000261428.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261437.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261438.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261451.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261455.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261469.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261534.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000261572.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261646.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261654.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261690.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261692.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261760.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261770.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000261775.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261780.2 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000261790.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261799.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261799.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000261801.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000261801.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000261804.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000261823.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000261827.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000261827.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000261840.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000261864.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000261879.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000261879.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000261916.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000261916.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000261996.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000262089.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000262094.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000262115.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000262115.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000262172.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000262179.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000262185.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000262202.3 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000262222.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000262228.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000262265.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000262265.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000262294.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000262298.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000262312.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000262319.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000262362.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000262410.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000262434.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000262434.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000262445.3 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000262585.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000262678.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000262686.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000262692.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000262714.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000262772.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000262823.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000262823.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000262823.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000262833.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000262877.3 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000262903.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000262952.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000262979.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000263004.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000263015.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000263050.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000263069.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000263080.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000263214.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000263220.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000263257.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000263280.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000263325.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000263370.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000263388.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000263443.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000263627.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000263709.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000263718.2 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000263731.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000263786.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000263847.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000263859.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000263893.2 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000263916.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000263931.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000263931.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000264007.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000264083.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000264107.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000264107.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000264112.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000264167.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000264235.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000264243.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000264569.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000264647.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000264673.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000264829.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000264859.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000264920.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000264968.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000265113.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000265142.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000265206.2 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000265206.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000265218.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000265349.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000265349.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000265394.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000265443.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000265445.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000265478.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000265487.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000265542.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000265542.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000265666.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000265688.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000265702.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000265728.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000265750.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000265791.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000265791.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000265800.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000265888.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000265912.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000266088.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266149.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000266278.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266304.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266368.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266371.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000266401.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000266445.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000266446.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266498.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000266521.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266538.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000266578.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000266601.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000266644.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000266644.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000266667.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266709.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000266718.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000266744.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000266824.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000266835.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000266844.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000266869.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266900.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000266903.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000266912.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000266912.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266912.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000266918.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000266921.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000266926.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266930.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266933.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266935.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266936.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000266942.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000266965.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000266965.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000266969.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000266993.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000266999.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267002.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000267006.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267025.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267025.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000267040.2 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267052.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267064.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000267065.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267069.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000267136.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000267136.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267136.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267141.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267161.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000267161.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267174.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000267174.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267197.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267198.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267219.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000267221.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000267246.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267249.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267249.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267280.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000267280.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000267284.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267288.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267288.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267289.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267298.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000267308.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000267308.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267308.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000267311.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267325.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000267327.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267344.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267344.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000267366.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267375.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000267437.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267462.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267470.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267476.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267505.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000267510.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000267546.2 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000267557.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267565.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267567.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267654.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000267672.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267682.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000267702.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267702.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267729.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267730.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000267734.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000267745.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000267750.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000267758.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000267758.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000267765.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000267778.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000267783.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000267785.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267787.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000267787.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000267798.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000267798.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000267838.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000267879.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000267940.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000268049.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000268061.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000268061.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000268189.2 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000268230.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000268230.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000268266.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000268460.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000268543.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000268605.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000268613.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000268707.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000268707.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000268743.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000268746.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000268756.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000268802.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000268913.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000268913.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000268913.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000268947.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000269082.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000269082.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000269107.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000269148.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000269172.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000269191.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000269194.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000269246.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000269352.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000269463.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000269481.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000269535.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000269574.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000269614.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000269640.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000269646.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000269652.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000269656.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000269680.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000269688.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000269873.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000269887.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000269887.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000269892.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000269894.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000269896.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000269906.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000269934.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000269942.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000269946.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000269950.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000269951.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000269956.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000269976.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000269980.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000269989.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000269990.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000269994.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000270000.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000270010.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000270018.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000270036.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000270052.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270083.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000270104.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270115.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000270115.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270124.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000270130.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000270141.2 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000270173.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270174.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000270177.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000270178.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270189.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270190.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270223.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270223.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000270223.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000270265.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000270265.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270346.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270361.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000270460.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000270557.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000270571.2 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000270640.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000270659.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000270720.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000270933.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000270933.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000270949.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000270964.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000271032.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000271151.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271172.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271204.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000271218.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271320.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000271327.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000271344.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000271366.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271366.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271420.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271427.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271430.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271538.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271553.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000271553.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000271555.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271579.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271631.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000271643.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000271716.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271716.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000271738.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000271751.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000271778.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000271778.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271780.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000271788.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271803.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000271815.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000271820.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000271826.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000271830.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271845.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271856.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000271871.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000271871.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271882.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271912.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271917.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271921.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271948.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271963.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000271963.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000271966.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000271983.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000271983.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000271997.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000272002.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272005.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000272009.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272023.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000272030.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272048.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272049.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272070.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272071.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272072.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272079.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272091.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272091.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272092.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272123.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000272129.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272130.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272141.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272161.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000272211.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000272216.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000272217.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272240.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272248.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000272263.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272275.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000272308.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272312.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272316.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272316.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272320.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272334.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272334.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272341.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272346.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272354.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272374.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272375.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000272384.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272403.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000272420.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272438.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272438.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000272440.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272446.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000272449.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000272449.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272449.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000272452.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272452.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272459.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272472.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000272489.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272505.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000272512.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272516.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000272529.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272529.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000272541.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272544.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272554.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272556.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000272562.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272562.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000272567.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272588.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000272604.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272627.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272657.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272666.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272672.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272672.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000272677.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272682.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000272690.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000272691.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272695.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272695.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272699.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272707.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272717.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272721.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272732.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272732.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000272733.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272744.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272746.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272761.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000272787.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272798.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272810.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272812.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272832.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272832.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000272832.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000272861.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272862.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272864.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000272894.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272905.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000272912.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272933.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000272954.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272970.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000272977.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000272983.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000272993.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000273001.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000273007.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000273008.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000273009.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000273033.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000273058.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000273059.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000273065.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273066.1 |
Predicted lncRNA |
Cervical squamouscell carcinoma and endocervical adenocarcinoma |
|
| Gefitinib |
ENSG00000273081.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273084.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000273091.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273104.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273116.1 |
Predicted lncRNA |
Stomach adenocarcinoma |
|
| Gefitinib |
ENSG00000273118.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273125.1 |
Predicted lncRNA |
Head and neck squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273129.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000273131.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000273139.1 |
Predicted lncRNA |
Thyroid carcinoma |
|
| Gefitinib |
ENSG00000273156.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000273190.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000273213.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000273213.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000273218.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000273218.1 |
Predicted lncRNA |
Esophageal cancer |
|
| Gefitinib |
ENSG00000273230.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000273237.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
ENSG00000273253.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273271.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000273295.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273313.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000273328.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000273335.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000273335.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273338.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000273341.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000273356.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000273365.1 |
Predicted lncRNA |
Brain lower grade glioma |
|
| Gefitinib |
ENSG00000273373.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000273373.1 |
Predicted lncRNA |
Chronic Lymphocytic Leukemia |
|
| Gefitinib |
ENSG00000273375.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000273381.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000273381.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000273399.1 |
Predicted lncRNA |
Breast invasive carcinoma |
|
| Gefitinib |
ENSG00000273399.1 |
Predicted lncRNA |
Kidney renal clear cell carcinoma |
|
| Gefitinib |
ENSG00000273402.1 |
Predicted lncRNA |
Sarcoma |
|
| Gefitinib |
ENSG00000273406.1 |
Predicted lncRNA |
Bladder urothelial carcinoma |
|
| Gefitinib |
ENSG00000273454.1 |
Predicted lncRNA |
Skin cutaneous melanoma |
|
| Gefitinib |
ENSG00000273483.1 |
Predicted lncRNA |
Lung squamous cell carcinoma |
|
| Gefitinib |
ENSG00000273487.1 |
Predicted lncRNA |
Ovarian serous cyStomach adenocarcinomaenocarcinoma |
|
| Gefitinib |
ENSG00000273487.1 |
Predicted lncRNA |
Pancreatic adenocarcinoma |
|
| Gefitinib |
let-7c |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
let-7e |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
lnc-TMEM30B-3 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
LOC100129554 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-100 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-10b |
Curated miRNA |
Non-small Cell Lung Cancer |
|
| Gefitinib |
miR-122 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-124c |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-125 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-125b |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-126 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-127 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-130a |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-130a |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-132 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-133b |
Curated miRNA |
non-small-cell lung cancer |
|
| Gefitinib |
miR-134 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-138 |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-140 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-142 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-143 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-145 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-146a |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-146a |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-147 |
Curated miRNA |
colorectal cancer |
|
| Gefitinib |
miR-148a |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-155 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-181 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-200a |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-200c |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-205 |
Curated miRNA |
breast cancer |
|
| Gefitinib |
miR-21 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-21 |
Curated miRNA |
Non-small Cell Lung Cancer |
|
| Gefitinib |
miR-214 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-214 |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-22 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-221 |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-222 |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-224 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-24-1 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-27b |
Curated miRNA |
kidney cancer |
|
| Gefitinib |
miR-27b |
Curated miRNA |
liver cancer |
|
| Gefitinib |
miR-299 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-30b |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-30b |
Curated miRNA |
non-small cell lung cancer |
|
| Gefitinib |
miR-30c |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-31 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-34a |
Curated miRNA |
non-small-cell lung cancer |
|
| Gefitinib |
miR-374a |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-375 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-376a |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-423 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-424 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-483 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-487b |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-494 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-497 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-505 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-548b |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-572 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-638 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-660 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-7 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-7 |
Curated miRNA |
lung cancer |
|
| Gefitinib |
miR-720 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-744 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-762 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-766 |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-92a |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
miR-99a |
Curated miRNA |
lung adenocarcinoma |
|
| Gefitinib |
NR_026685 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
RNPS1P1 |
Curated lncRNA |
non-small cell lung cancer |
|
| Gefitinib |
RPL23P11 |
Curated lncRNA |
non-small cell lung cancer |
|
